Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001843981 | SCV002103231 | pathogenic | not provided | 2022-01-24 | criteria provided, single submitter | clinical testing | PP1, PP4, PM3_very_strong, PS3_supporting |
Labcorp Genetics |
RCV001843981 | SCV003441321 | pathogenic | not provided | 2024-12-20 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 1217 of the ADAMTS13 protein (p.Ile1217Thr). This variant is present in population databases (rs200847393, gnomAD 0.02%). This missense change has been observed in individual(s) with thrombotic thrombocytopenic purpura (PMID: 18481107, 23870247, 26085195, 30792199, 31874663). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 1343360). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV005040408 | SCV005678096 | pathogenic | Upshaw-Schulman syndrome | 2024-01-11 | criteria provided, single submitter | clinical testing |